Skip to main content
Erschienen in: Endocrine Pathology 4/2015

01.12.2015

Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid

verfasst von: Guo-Xia Tong, Kokila Mody, Zhuo Wang, Diane Hamele-Bena, Marina N. Nikiforova, Yuri E. Nikiforov

Erschienen in: Endocrine Pathology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Clear cell follicular carcinoma is a rare type of thyroid cancer and some with aggressive biological behavior. The cytoplasmic clearing of the neoplastic cells has been attributed to the accumulation of various substances, such as glycogen, lipid, mucin, and thyroglobulin, or distension of mitochondria or endoplasmic reticulum. However, the molecular mechanisms responsible for the characteristic appearance of the cell cytoplasm and the biological behavior remain unknown. We report here a case of aggressive clear cell follicular carcinoma of the thyroid with molecular profile using targeted next generation sequencing (NGS) that presented as a metastatic tumor in a woman with a history of breast carcinoma. The NGS data revealed the coexisting of a well-characterized loss-of-function TP53 R248Q mutation and a putative gain-of-function mutation of TSHR L272V, which was suggested by the overexpression of thyroglobulin and SLC5A5 (NIS) genes in this tumor. TP53 mutations are usually related with dedifferentiation, progression, and metastasis of thyroid carcinomas. Identification of TP53 R248Q in this tumor correlated with its aggressive clinical behavior. Gain-of-function mutation of TSHR can overstimulate the thyroid follicular cells as the elevated level of TSH does and might have contributed to the development of clear cell morphology in this tumor. This report represents the first case of clear cell follicular carcinoma of the thyroid with NGS analysis and more molecular characterization is needed to elucidate the pathogenesis and provide more prognosis-relevant information for this uncommon variant of thyroid carcinomas.
Literatur
1.
Zurück zum Zitat Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 1985;9:705–22.CrossRefPubMed Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 1985;9:705–22.CrossRefPubMed
2.
Zurück zum Zitat Civantos F, Albores-Saavedra J, Nadji M, Morales AR. Clear cell variant of thyroid carcinoma. Am J Surg Pathol 1984;8:187–92.CrossRefPubMed Civantos F, Albores-Saavedra J, Nadji M, Morales AR. Clear cell variant of thyroid carcinoma. Am J Surg Pathol 1984;8:187–92.CrossRefPubMed
3.
Zurück zum Zitat Schroder S, Bocker W. Clear-cell carcinomas of thyroid gland: a clinicopathological study of 13 cases. Histopathology 1986;10:75–89.CrossRefPubMed Schroder S, Bocker W. Clear-cell carcinomas of thyroid gland: a clinicopathological study of 13 cases. Histopathology 1986;10:75–89.CrossRefPubMed
4.
Zurück zum Zitat Ropp BG, Solomides C, Palazzo J, Bibbo M. Follicular carcinoma of the thyroid with extensive clear-cell differentiation: a potential diagnostic pitfall. Diagn Cytopathol 2000;23:222–3.CrossRefPubMed Ropp BG, Solomides C, Palazzo J, Bibbo M. Follicular carcinoma of the thyroid with extensive clear-cell differentiation: a potential diagnostic pitfall. Diagn Cytopathol 2000;23:222–3.CrossRefPubMed
5.
Zurück zum Zitat Andrews GA, Kniseley RM. Transformation of thyroidal carcinoma to clear-cell type. Am J Clin Pathol 1956;26:1427–38.PubMed Andrews GA, Kniseley RM. Transformation of thyroidal carcinoma to clear-cell type. Am J Clin Pathol 1956;26:1427–38.PubMed
6.
Zurück zum Zitat Jayaram G. Cytology of clear cell carcinoma of the thyroid. Acta Cytol 1989;33:135–6.PubMed Jayaram G. Cytology of clear cell carcinoma of the thyroid. Acta Cytol 1989;33:135–6.PubMed
7.
Zurück zum Zitat Woolner LB, Beahrs OH, Black BM, Mc CW, Keating FR, Jr. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961;102:354–87.CrossRefPubMed Woolner LB, Beahrs OH, Black BM, Mc CW, Keating FR, Jr. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961;102:354–87.CrossRefPubMed
8.
Zurück zum Zitat Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627–34.CrossRefPubMed Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627–34.CrossRefPubMed
9.
Zurück zum Zitat Peter I, Besznyak I, Szanto J, et al. Clear cell thyroid cancer—undifferentiated type—an immunohistochemical and electron microscopical study. Arch Geschwulstforsch 1989;59:121–8.PubMed Peter I, Besznyak I, Szanto J, et al. Clear cell thyroid cancer—undifferentiated type—an immunohistochemical and electron microscopical study. Arch Geschwulstforsch 1989;59:121–8.PubMed
10.
Zurück zum Zitat Koike A, Naruse T, Kanemitsu T, et al. Clear cell carcinoma of the thyroid. A case report. Jpn J Surg 1989;19:237–40.CrossRefPubMed Koike A, Naruse T, Kanemitsu T, et al. Clear cell carcinoma of the thyroid. A case report. Jpn J Surg 1989;19:237–40.CrossRefPubMed
11.
Zurück zum Zitat Harach HR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 1988;13:43–54.CrossRefPubMed Harach HR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 1988;13:43–54.CrossRefPubMed
12.
Zurück zum Zitat Dayal Y, Ucci AA, Safaii H, Pohl D. Thyroglobulin and clear-cell tumors. Am J Surg Pathol 1986;10:70–2.CrossRefPubMed Dayal Y, Ucci AA, Safaii H, Pohl D. Thyroglobulin and clear-cell tumors. Am J Surg Pathol 1986;10:70–2.CrossRefPubMed
13.
Zurück zum Zitat Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol 2011;35:757–61.PubMedCentralCrossRefPubMed Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol 2011;35:757–61.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Diaz-Arias AA, Bickel JT, Loy TS, et al. Follicular carcinoma with clear cell change arising in lingual thyroid. Oral Surg Oral Med Oral Pathol 1992;74:206–11.CrossRefPubMed Diaz-Arias AA, Bickel JT, Loy TS, et al. Follicular carcinoma with clear cell change arising in lingual thyroid. Oral Surg Oral Med Oral Pathol 1992;74:206–11.CrossRefPubMed
15.
Zurück zum Zitat Cassio A, Nicoletti A, Rizzello A, et al. Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatment. J Clin Res Pediatr Endocrinol 2013;5 Suppl 1:29–39.PubMedCentralPubMed Cassio A, Nicoletti A, Rizzello A, et al. Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatment. J Clin Res Pediatr Endocrinol 2013;5 Suppl 1:29–39.PubMedCentralPubMed
16.
Zurück zum Zitat Kleinau G, Biebermann H. Constitutive activities in the thyrotropin receptor: regulation and significance. Adv Pharmacol 2014;70:81–119.CrossRefPubMed Kleinau G, Biebermann H. Constitutive activities in the thyrotropin receptor: regulation and significance. Adv Pharmacol 2014;70:81–119.CrossRefPubMed
17.
Zurück zum Zitat Latif R, Ali MR, Ma R, et al. New small molecule agonists to the thyrotropin receptor. Thyroid 2015;25:51–62.CrossRefPubMed Latif R, Ali MR, Ma R, et al. New small molecule agonists to the thyrotropin receptor. Thyroid 2015;25:51–62.CrossRefPubMed
18.
Zurück zum Zitat Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001;14:289–96.CrossRefPubMed Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001;14:289–96.CrossRefPubMed
19.
Zurück zum Zitat Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90.
20.
Zurück zum Zitat Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:955–69.PubMedCentralCrossRefPubMed Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:955–69.PubMedCentralCrossRefPubMed
22.
23.
Zurück zum Zitat Yoshikawa K, Hamada J, Tada M, et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res 2010;31:401–11.CrossRefPubMed Yoshikawa K, Hamada J, Tada M, et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res 2010;31:401–11.CrossRefPubMed
24.
Zurück zum Zitat Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 2001;72:155–63.CrossRefPubMed Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 2001;72:155–63.CrossRefPubMed
25.
Zurück zum Zitat Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753–60.PubMedCentralCrossRefPubMed Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753–60.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–84.PubMedCentralCrossRefPubMed Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–84.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369–71.PubMed Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369–71.PubMed
Metadaten
Titel
Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid
verfasst von
Guo-Xia Tong
Kokila Mody
Zhuo Wang
Diane Hamele-Bena
Marina N. Nikiforova
Yuri E. Nikiforov
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2015
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9388-1

Weitere Artikel der Ausgabe 4/2015

Endocrine Pathology 4/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …